NEW DELHI: According to a report by ET Now, pharma giant GlaxoSmithKline Pharmaceuticals Ltd has been actively seeking in-licensing deals with global MNCs.
The report states that the company is presently under discussions with 3 parties for in-licensing deals in Derma, Respiratory & Antibiotic areas.
GSK’s email from the management noted, “In licensing is a part of our growth strategy and we are constantly looking for opportunities which we announce only when an arrangement is crystallized.”
Research & Development expenses in the pharma industry are costly and take up a lot of time and resources. Through in-licensing deals, companies can leverage their options to strengthen their base by attaining the rights to molecules developed by other companies or research departments.
The rights acquired through in-licensing deals will enable the company to decrease expenses, remain competitive, and boost in-organic growth.
At 12:00 PM IST, company shares were trading 0.4% lesser at INR 2113 on BSE. For the year, the stock has dropped a little more than 10%.